Is Novavax Inc (NVAX) a Stock to Watch After Gaining 4.27% This Week?

Novavax Inc (NVAX) stock has gained 4.27% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Novavax Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on NVAX!

See Full NVAX Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With NVAX Stock Today?

Novavax Inc (NVAX) stock is up 5.03% while the S&P 500 is down -1.03% as of 10:24 AM on Monday, Dec 5. NVAX is higher by $0.83 from the previous closing price of $16.52 on volume of 1,843,101 shares. Over the past year the S&P 500 is down -12.24% while NVAX is down -87.77%. NVAX lost -$17.25 per share in the over the last 12 months. To screen for more stocks like Novavax Inc click here.

More About Novavax Inc

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population. Click Here to get the full Stock Report for Novavax Inc stock.